Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric Antigen Receptor T-cell) treatments.

Hannah Abrams, MD, discusses the key takeaways of research into nonmedical barriers to HCT and CAR T therapy. Research led by Hannah Abrams, MD, fellow in hematolog-oncology at Fred Hutch Cancer ...

Hannah Abrams, MD, discusses the background behind research into nonmedical barriers to cell transplant and CAR T therapy.

Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these ...

South Korea-based DAAN Biotherapeutics has entered a licensing agreement with GC Cell, granting the latter exclusive rights ...

CAR T-cell therapy showed encouraging efficacy and good safety in newly diagnosed Ph-positive ALL,” the researchers wrote.

In part 4 of an interview with The American Journal of Managed Care®, Frederick L. Locke, MD, provides insight on the design ...

A newly developed radiolabeled antibody that targets the cancer antigen IL13Rα2 has been found to be highly specific, binding ...

More than five years have passed since the arrival in Italy of the first anti -cancer gene therapy, the Car-t ...

A team of researchers has successfully created more effective immune cells that can fight cancer without damaging healthy tissue.

Tolerogenic dendritic cells in the intestines are shown to reduce the immune responses caused by exposure to food proteins.

FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient ...